3.07 USD
▲+0.16+2.33%
盘后 2.99 -0.33%
2026-08-03
市值
$597.04M
市盈率
—
EPS
-0.91
股息率
—
52 周区间
2.56 – 6.44
成交量
8.16M
Beta
0.24
目标价
17.22
52W 低 2.5652W 高 6.44
价格走势
公司简介
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.